

Clinical criteria updates for specialty pharmacy

Published: Feb 1, 2020 - **Products & Programs** / Pharmacy

The following clinical criteria documents were endorsed at the November 15, 2019 Clinical Criteria meeting. To access the clinical criteria information please click [here](#).

If you do not have access to the internet, you may request a hard copy of any updated policy by contacting the [Provider Call Center](#).

Revised clinical criteria effective December 16, 2019

The following clinical criteria was revised to expand medical necessity indications or criteria.

- ING-CC-0003: Immunoglobulins
- ING-CC-0041: Complement Inhibitors
- ING-CC-0042: Monoclonal Antibodies to Interleukin-17
- ING-CC-0063: Stelara (ustekinumab)
- ING-CC-0065: Agents for Hemophilia A and von Willebrand Disease
- ING-CC-0075: Rituximab Agents for Non-Oncology Indications
- ING-CC-0124: Keytruda (pembrolizumab)
- ING-CC-0127: Darzalex (daratumumab)
- ING-CC-0128: Tecentriq (atezolizumab)
- ING-CC-0133: Aliqopa (copanlisib)

Revised clinical criteria effective December 16, 2019

The following clinical criteria were reviewed and may have word changes or clarifications, but had no significant changes to the medical necessity indications or criteria.

- ING-CC-0002: Colony Stimulating Factor Agents
- ING-CC-0006: Hyaluronan Injections
- ING-CC-0035: Duopa (carbidopa and levodopa enteral suspension)
- ING-CC-0039: GamaSTAN [immune globulin (human)]
- ING-CC-0040: Prialt (ziconotide)

- ING-CC-0043: Monoclonal Antibodies to Interleukin-5
- ING-CC-0047: Trogarzo (ibalizumab-uiyk)
- ING-CC-0049: Radicava (edaravone)
- ING-CC-0062: Tumor Necrosis Factor Antagonists
- ING-CC-0073: Alpha-1 Proteinase Inhibitor Therapy
- ING-CC-0074: Akynzeo (fosnetupitant and palonosetron) for Injection
- ING-CC-0079: Strensiq (asfotase alfa)
- ING-CC-0090: Ixempra (ixabepilone)
- ING-CC-0100: Istodax (romidepsin)
- ING-CC-0103: Faslodex (fulvestrant)
- ING-CC-0108: Halaven (eribulin)
- ING-CC-0110: Perjeta (pertuzumab)
- ING-CC-0115: Kadcyla (ado-trastuzumab)

New clinical criteria effective February 5, 2020

The following new clinical criteria was previously a medical policy and was revised to expand medical necessity indications or criteria.

- ING-CC-0151: Yescarta (axicabtagene ciloleucel) (previously MED.00123)

New clinical criteria effective February 5, 2020

The following new clinical criteria was previously a medical policy and was revised with no significant change to the medical necessity indications or criteria.

- ING-CC-0150: Kymriah (tisagenlecleucel) (previously MED.00124)

Revised clinical criteria effective May 1, 2020

The following current clinical criteria were revised and might result in services that were previously covered but may now be found to be not medically necessary.

- ING-CC-0002: Colony Stimulating Factor Agents
- ING-CC-0003: Immunoglobulins
- ING-CC-0034: Hereditary Angioedema Agents
- ING-CC-0041: Complement Inhibitors
- ING-CC-0042: Monoclonal Antibodies to Interleukin-17
- ING-CC-0043: Monoclonal Antibodies to Interleukin-5

- ING-CC-0048: Spinraza (nusinersen)
- ING-CC-0050: Monoclonal Antibodies to Interleukin-23
- ING-CC-0062: Tumor Necrosis Factor Antagonists
- ING-CC-0063: Stelara (ustekinumab)
- ING-CC-0064: Interleukin-1 Inhibitors
- ING-CC-0065: Agents for Hemophilia A and von Willebrand Disease
- ING-CC-0066: Monoclonal Antibodies to Interleukin-6
- ING-CC-0071: Entyvio (vedolizumab)
- ING-CC-0072: Selective Vascular Endothelial Growth Factor (VEGF) Antagonists
- ING-CC-0078: Orencia (abatacept)
- ING-CC-0150: Kymriah (tisagenlecleucel)

New clinical criteria effective May 1, 2020

The following new clinical criteria had content transferred from existing criteria and was revised with no significant change to the medical necessity indications or criteria.

- ING-CC-0148: Agents for Hemophilia B (content moved from ING-CC-0065)

New clinical criteria effective May 1, 2020

The following new clinical criteria had content transferred from existing criteria and was revised, which might result in services that were previously covered but may now be found to be not medically necessary.

- ING-CC-0149: Select Clotting Agents for Bleeding Disorders (content moved from ING-CC-0065)

URL: <https://providernews.anthem.com/connecticut/article/clinical-criteria-updates-for-specialty-pharmacy-38>

Featured In:

February 2020 Anthem Connecticut Provider News

Anthem Blue Cross and Blue Shield is the trade name of: In Colorado Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. In Connecticut: Anthem Health Plans, Inc. In Georgia: Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. In Indiana: Anthem Insurance Companies, Inc. In Kentucky: Anthem Health Plans of Kentucky, Inc. In Maine: Anthem Health Plans of Maine, Inc. In Missouri (excluding 30 counties in the Kansas City area): RightCHOICE® Managed Care, Inc. (RIT), Healthy Alliance® Life Insurance Company (HALIC), and HMO Missouri, Inc. RIT and certain affiliates administer non-HMO benefits underwritten by HALIC and HMO benefits underwritten by HMO Missouri, Inc. RIT and certain affiliates only provide administrative services for self-funded plans and do not underwrite benefits. In Nevada: Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. dba HMO Nevada. In New Hampshire: Anthem Health Plans of New Hampshire, Inc. HMO plans are administered by Anthem Health Plans of New Hampshire, Inc. and underwritten by Matthew Thornton Health Plan, Inc. In Ohio: Community Insurance Company. In Virginia: Anthem Health Plans of Virginia, Inc. trades as Anthem Blue Cross and Blue Shield in Virginia, and its service area is all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123. In Wisconsin: Blue Cross Blue Shield of Wisconsin (BCBSWI), which underwrites or administers the PPO and indemnity policies

and underwrites the out of network benefits in POS policies offered by Compcare or WCIC; Compcare Health Services Insurance Corporation (Compcare) underwrites or administers the HMO policies and Wisconsin Collaborative Insurance Company (WCIC) underwrites or administers Well Priority HMO or POS policies. Independent licensees of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Use of the Anthem websites constitutes your agreement with our Terms of Use.
